To study ROCK2 activation in carcinogenesis, mice expressing 4-hydroxytamoxifen (4HT) er /pMypt1 expression, as cessation of 4HT treatment induced disorganized tissue architecture and p21-associated differentiation in wdSCCs; yet tenascin C retention in connective tissue extracellular matrix suggests the rigidity laid down for conversion persists. Novel papilloma outgrowths appeared expressing intense, basal layer p21 that confined endogenous ROCK2/p-Mypt1/NF-κB to supra-basal layers, and was paralleled by restored basal layer p53. In later SCCs, 4HT cessation became irrelevant as endogenous ROCK2 expression increased, driving progression via p21 loss, elevated NF-κB expression and tenascin C-associated rigidity, with p-Mypt1 inactivation/actinomyosin-mediated contractility to facilitate invasion. However, p21-associated inhibition of early-stage malignant progression and the intense expression in papilloma outgrowths, identifies a novel, significant antagonism between p21 and ras Ha /ROCK2/NF-κB signalling in skin carcinogenesis. Collectively, these data show that ROCK2 activation induces malignancy in ras Ha -initiated/promoted papillomas in the context of p53 loss and novel NF-κB expression, whereas increased tissue rigidity and cell motility/contractility help mediate tumour progression.
INTRODUCTION

ROCK2, an effector of RhoA signalling downstream of ras
Ha , has essential roles in the regulation of actomyosin contraction and cellular tension during normal regulation of proliferation and differentiation.
1,2 ROCK2 acts to regulate cellular motility through the phosphorylation of LIM kinases (LIMK), myosin regulatory light chains (MLC2) and myosin-binding subunit to inhibit MLC phosphatase (Mypt1). Thus, in carcinogenesis, deregulated ROCK2 signalling and Mypt1 inactivation increases actomyosinmediated cellular tension and collagen deposition that alters the extracellular matrix (ECM) to increase tissue rigidity, [3] [4] [5] [6] [7] [8] alongside increased cell contractibility/motility that facilitates invasion. [4] [5] [6] This increased matrix density changes integrin clustering and increases proliferation via signalling through FAK downregulates GSK3β and increases β-catenin, 5, 6 whereas additional signal transduction pathways [9] [10] [11] [12] provide a matrix permissive for tumour progression. [4] [5] [6] 13 This association with invasion and metastasis, plus the fact that ROCK proteins act as effectors downstream of ras signalling, makes ROCK inhibition an attractive therapeutic target, 3, 8 particularly as rasspecific inhibitors have proved unsuccessful. 14 However, few transgenic studies have directly explored activated ROCK2/ras Ha synergism. Classic DMBA/TPA skin carcinogenesis employing 4HT-inducible ROCK2 mice (K14.ROCK er ) 15 implicated synergism with ras Ha activation 16 as papilloma conversion rates increased, 5 but given the numerous mutations elicited by DMBA initiation 16 direct ROCK2/ras Ha co-operation remains unclear and potential synergism in earlier papillomatogenesis uncertain. Thus, to ratify ras/ROCK2 synergism, identify stage-specific causality and explore the unfolding progression mechanism, 4HT-inducible K14.ROCK er mice were bred into a well-characterized model of ras Ha -driven mouse skin carcinogenesis. [17] [18] [19] [20] Here exclusive epidermal v-ras Ha expression induces wound-dependent, regression-prone papillomas (HK1. ras 1205 ) or epidermal hyperplasia alone (HK1.ras 1276 ), 17 phenotypes ideal to assess ROCK2/ras synergism in papilloma formation and 1 Section of Dermatology and Molecular Carcinogenesis, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, Glasgow University, Glasgow, UK; malignant conversion/progression, [17] [18] [19] [20] and assess the effects on epidermal differentiation. 21, 22 In this model, activated ROCK2/ras Ha co-operation induced malignant conversion via p53 loss, increasing the numbers of proliferating cells prone to DNA damage, novel ROCK2-associated increase in NF-κB expression and elevated tenascin C, indicative of tissue rigidity. However, earlier ROCK2/ras Ha synergism in papilloma aetiology required both ras Ha activation and a (wound) promotion stimulus. Furthermore, compensatory p21 expression in well-differentiated squamous cell carcinomas (wdSCCs) inhibited early-stage malignancy, requiring p21 loss to progress to aggressive SCC. Cessation of 4HT treatment demonstrated that malignant conversion depended upon continued 4HT-mediated ROCK er /endogenous ROCK2 activation; however, novel papilloma outgrowths appeared expressing intense p21 levels in proliferative basal layer keratinocytes that confined (endogenous) ROCK2/pMypt1/NF-κB expression to supra-basal, differentiating layers, accompanied by return of p53 expression to prevent relapse. These data confirm ROCK2/ras Ha synergism drives both malignant conversion and malignant progression, and identify a significant antagonism between p21 responses following p53 loss and ROCK2/NF-κB/tenascin C signalling in ras Ha skin carcinogenesis.
RESULTS
ROCK2 activation co-operates with ras
Ha to elicit malignant conversion but a tumour promotion stimulus is required to develop papillomas To investigate deregulated ROCK2 signalling synergism with ras Ha activation in classic mouse skin carcinogenesis, K14.ROCK er mice were initially bred into line HK1.ras 1205 that expressed activated v-ras Ha exclusively in transit amplifying keratinocytes of the epidermal basal layer and required a promotion stimulus (TPA/ear-tag wounding) to develop wound-sensitive papillomas that do not spontaneously convert to malignancy. [17] [18] [19] In addition, to investigate the requirement for wound promotion, K14.ROCK er mice were also bred into a wound-insensitive HK1.ras 1276 line that exhibits hyperplasia alone unless treated with TPA or acquires an additional, appropriate oncogenic insult. [17] [18] [19] [20] In repeat experiments, performed over a 12-month period, cohorts of agematched, bi-genic K14.ROCK er /HK1.ras 1205 , HK1.ras 1205 and K14. ROCK er siblings were treated with 4HT for 8-10 weeks (n = 12), 10-12 weeks (n = 12) and 14-16 weeks (n = 8), respectively, with controls (n = 6 per cohort per experiment) receiving ethanol alone (Figures 1a-d Figure 1a) . [17] [18] [19] All 4HT-treated K14.ROCK er /HK1.ras 1205 followed this aetiology, unless mice lost the wound promotion stimulus from ear tags and if so regardless of treatment/genotype (n = 9), such tumours remained small or regressed (Figure 1d ; Supplementary Figure S1) . 17, 18 This requirement for a wound promotion stimulus was directly assessed in 4HT-treated K14. ROCK er /HK1.ras 1276 mice (n = 9 per cohort). In repeat experiments, these mice failed to develop overt papillomas regardless of eartag wounding, over the thrice weekly/20-week treatment regime (Figure 1e ), although hyperplasia did increase in all 4HT-treated K14.ROCK er /HK1.ras 1276 mice (n = 18; Supplementary Figure S1 ). At 8 weeks, untreated K14.ROCK er /HK1.ras 1205 tumours exhibited a squamous cell papilloma histotype (Figure 1f ) indistinguishable from 4HT-treated HK1.ras controls, with a well-ordered, sequential keratinocyte differentiation pattern, and strong supra-basal keratin K1 expression (Figure 3g ) indicative of benign tumours. [17] [18] [19] [20] However, all 4HT-treated K14.ROCK er /HK1.ras 1205 tumours exhibited a mixed histotype of papilloma and wdSCC (Figure 1g ; n = 24), which by 12 weeks progressed to uniform wdSCCs (Figure 1h ; n = 24) possessing a disordered basal layer and strands of aggressive SCC (Figures 1i and j) . In repeat experiments, by 14-16 weeks, all 4HT-treated K14.ROCK er /HK1.ras 1205 tumours (n = 16) progressed to aggressive SCC ( Figure 2C ), whereas no evidence of malignant conversion was observed in untreated controls (n = 12) or HK1.ras (n = 12). [17] [18] [19] Malignant conversion to wdSCC was confirmed by reduced keratin K1 expression [17] [18] [19] [20] already apparent in 8-week tumours (Figure 1k ), which reduced further and was subsequently lost as wdSCCs (Figure 1l ) on progressed to K1-negative SCCs (see time course, Figure 2C ), whereas all control tumours exhibited a supra-basal K1 expression profile consistent with a papilloma histotype. (Figures 2Ai-l) . As reported previously, 5, 15 4HT-treated K14.ROCK er mice exhibit mild hyperplasia without signs of papillomatogenesis (20 weeks), even after prolonged, thrice weekly treatments over 9 months (Figure 2Aa ), whereas HK1.ras mice exhibited a more severe epidermal hyperplasia (Figure 2Ai) . 17 Exogenous ROCK er expression was distinguished from endogenous ROCK2 via GFP tag expression, absent in HK1.ras controls (Figures 2Ab and f vs Figure 2Aj ). ROCK er activation by 4HT treatment was confirmed via p-Mypt1 expression (Figure 2Ac ), which appeared in all epidermal compartments including basal layers, consistent with ROCK er expression from the K14 promoter. 15 In untreated controls, p-Mypt1 expression was low/undetectable, whereas 4HT-treated, hyperplastic HK1.ras epidermis exhibited a low, supra-basal p-Mypt1 expression profile (Figure 2Ak ). Analysis of endogenous ROCK2 expression and in 4HT-treated K14.ROCK er cohorts, ROCK2-specific antibodies detected endogenous ROCK2 expression in spinous keratinocytes and weaker ROCK er expression in proliferative basal layers, as shown at a junction between 4HT-treated and -untreated skin (Figure 2Ad vs Figure 2Ah ). Here 4HT-treated HK1.ras epidermis exhibited low, supra-basal ROCK2 expression, consistent with p-Mypt1 staining (Figure 2Al ). Given that ROCK2-specific antibodies detected exogenous ROCK er expression in K14. ROCK er basal layer keratinocytes following 4HT treatment, whereas untreated skin or hyperplastic HK1.ras keratinocytes exhibited endogenous ROCK2 in supra-basal layers, it suggests that 4HT treatment increased/stabilized ROCK er expression 15 and that ROCK2 functions primarily in differentiated keratinocytes to provided the tensile strength to the spinous layers. 21 (Figures 2e and f) . − SCC (scale bars:~100 μm (i-k);~50 μm (f, g, h, l).
ras/ROCK2 co-operation in transgenic mouse skin SF Masre et al assessment, [17] [18] [19] [20] shows that strong, supra-basal expression in benign HK1.ras papillomas becomes reduced in wdSCC/SCC nests and is lost on progression to invasive SCC (Figures 2Cg-i also exhibited areas of reduced p53 expression not seen in controls, beginning in basal layers giving a weaker, cytoplasmic expression in the post-mitotic supra-basal layers (Figure 3Ac ). This ras/ROCK2 co-operation in transgenic mouse skin SF Masre et al it suggests a direct antagonism between ROCK er signalling and p21, an idea supported by the relative lack of a significant proliferation increase following conversion as determined by BrdU labelling (below; Figure 3C ), plus the intriguing, intense p21 expression observed following cessation of 4HT treatment ( Figure 5 ).
Given previous studies detected deregulated ROCK2 signalling effected cell proliferation 5 plus indications of a ROCK er /p21 antagonism, cell proliferation rates were assessed in stagespecific tumours via BrdU labelling ( Figure 3C ). Consistent with the mild hyperplasia observed, 4HT-treated K14.ROCK er epidermis possessed a mitotic index approximately double that in normal 4HT-treated skins (Figures 3Ca and b) but less than HK1.ras epidermis, [17] [18] [19] which exhibited a greater degree of hyperplasia (Figure 3Cc) , and a labelling similar to untreated/treated HK1.ras papillomas (Figure 3Cd; A detailed analysis 2 weeks post 4HT cessation found that earlier wdSCC cohorts (12 weeks; Figure 4Ba ) exhibited areas of disturbed basal layer architecture, with disorganized keratinocytes and intercellular spaces, suggesting a loss of cell-cell integrity ( Figure 4Bb ) and an increased acanthosis (expansion of the spinous layer), suggesting elevated differentiation, whereas other areas appeared to be progressing to SSC (Figure 4Ba ; black vs yellow box). Increasing K1 expression at these disorganized sites (Figure 4Bc ; white vs yellow box) also indicates a differentiation response, consistent with the appearance of elevated, basal layer p21 expression 20, 23, 24 throughout this tumour (Figure 4Bd ; black vs yellow box; and Figure 4Be ). However, unlike that observed in analysis of papilloma outgrowths (below) in this context, p53 expression did not return (Figure 4Bf ) a feature possibly due to the elevated NF-κB expression (Figure 6 ), hence the differentiation response rather than aopoptosis. 23 Typically following 4HT cessation, ROCK2 antibody analysis found decreased exogenous ROCK er /endogenous ROCK2 expression at these p21 + /K1 + sites and here expression became supra-basal also (Figures 4Bg and h) . Nonetheless, such wdSCCs possessed unaffected areas (Figures 4Ba, c and d ; yellow boxed areas), which had little K1/p21 and here endogenous, basal layer ROCK2 expression was detected (Figure 4Bi ) and activity confirmed by elevated p-Mypt1 expression (Figure 7 ), suggesting ROCK2 activation was required to maintain malignancy at this specific wdSCC stage.
Analysis of older K14.ROCK er /HK1.ras 1205 tumours support this conclusion, and as the 14-week tumours example shown (taken at 16 weeks) comprised highly invasive SCC and residual wdSCC (Figure 4Ca ; white vs larger yellow boxed area), it allowed a direct comparison of SCC and wdSCC within the same tissue section. This demonstrated that K1-negative SCC histotypes had now lost p21 on progression (Figures 4Cb, c and f) and now exhibited elevated, basal layer (endogenous) ROCK2 activation as determined by p-Mypt1 expression in the invasive SCC cells (Figures 4Cd, e and  g ). In contrast, residual wdSCC areas exhibiting disturbed tissue architecture, again expressed an increased K1/p21 profile and resultant basal-to-supra-basal transition of endogenous ROCK2 expression (Figures 4Ch-j) paralleled by reduced p-Mypt1 inactivation (Figure 7; below) . Thus, during the additional 2 weeks before treatment cessation, wdSCCs had progressed to a state where endogenous ROCK2 arose to substitute for 4HT-activated exogenous ROCK er and continued to drive malignant progression, as observed in other tumour types.
The intriguing lack of tumour regression exhibited by K14. ROCK er /HK1.ras 1205 carcinomas following 4HT cessation was unexpected, and the novel tumour outgrowths in particular were carefully re-examined ( Figure 5 ). Biopsies of all such outgrowths revealed a papilloma histotype, surprisingly devoid of wdSCC/SCC and keratin K1 expression confirmed their benign histotype (Figures 5a-c) . One feature of this analysis was that such tumour outgrowths repeatedly exhibited unusually intense p21 staining (Figures 5d-h ), and at these sites of intense p21 expression, another novel feature was the return of p53 re-expression (Figures 5i-l) as observed previously. 23 Indeed, employing standard p21 staining techniques, this intense p21 expression profile appeared unique to these specific K14.ROCK er /HK1.ras 1205 papilloma outgrowths when compared with analysis of similar histotypes (Figure 3, above) . Given that in previous studies, western analysis was compromised by varying levels of contaminating connective tissue and keratosis, 23 an attempt to semiquantify this aspect exploited p21 antibody titration. Several experiments utilizing sections from separate outgrowths (n = 6) found that a fourfold anti-p21 dilution (1/200) gave acceptable staining (Figures 5e-g ) in all layers, including basal layer nuclei (Figure 5h) . However, although similar analysis performed in parallel confirmed the return of p53 expression, again observed in all layer and basal layer nuclei (Figures 5i-l) , the 1/200 anti-p53 dilution repeatedly failed to detect significant expression levels.
Moreover, another striking characteristic was that, although endogenous ROCK2 levels remained elevated compared with untreated K14.ROCK er /HK1.ras 1205 papillomas (Figures 2Al and Cd), ROCK2 expression was now strictly confined to differentiated layers in p21-positive papillomas, a result paralleled by supra-basal p-Mypt1 expression (Figures 5m-p) . Collectively, these data suggest that malignant conversion depended upon ROCK2 activation, given that 12-week wdSCCs exhibited a dependence on ROCK er to maintain malignancy ( Figure 4B g-i) and 14-week tumours progressed to SCC due to endogenous ROCK2 expression, whereas intense, compensatory p21 staining reinforces the idea of a significant p21-mediated antagonism to ROCK2/ras Ha synergism in proliferative basal layers, which in this context enables return of p53 to prevent a relapse into malignancy. 20 (Figures 6Aa and b) . By 12 weeks, expression intensified, becoming prominent in the invasive fronts of wdSCCs, with many nuclear-positive basal layer keratinocytes (Figures 6Ac and d) . On progression to aggressive SCC, NF-κB expression became condensed and increasingly nuclear (Figures 6Ae-g ), concomitant ras/ROCK2 co-operation in transgenic mouse skin SF Masre et al with increasing endogenous ROCK2 and p21 loss (above). In contrast, untreated K14.ROCK er /HK1.ras 1205 papillomas (12 weeks; Figure 6Ah ) exhibited weak staining, suggesting NF-κB expression depended upon 4HT-activated ROCK er signalling, an idea also supported by detectable NF-κB in 4HT-treated K14.ROCK er but not HK1.ras 1205 hyperplasia (Figures 6Ai and j) that express low endogenous ROCK2 levels (Figure 2Ag and Cd).
This association of NF-κB with ROCK2 signalling was reinforced in 4HT cessation experiments ( Figure 6B ), although some stagespecific differences were observed. For instance, in wdSCC sections, the areas of disturbed tissue architecture and increasingly p21 (Figure 6Ba and b) , despite the reduction in exogenous ROCK er activation, thus possibly preventing the return of compensatory p53 expression. 25, 26 However, the unaffected areas that now expressed elevated, endogenous ROCK2 (Figures 4Ba, c and d (yellow boxed areas) ; Figure 4Bi ) also expressed elevated NF-κB. Indeed, following cessation, analysis of the later SSC (14 weeks) cohorts found that elevated NF-κB expression (Figures 6Bc and d) directly paralleled this increased endogenous ROCK2 and was concomitant with reduced p21 (Figure 4Ca-g ). In contrast, intensely p21 + papilloma outgrowths (Figures 5d-h ) exhibited reduced NF-κB levels with little basal layer expression (Figures 6Be and f vs Figure 6Ab) , consistent with the restricted, now supra-basal ROCK2 expression (Figure 6Bg) , and thus this reduced NF-κB may facilitate the return of p53 expression to these papilloma basal layers (Figures 5i-l) . Collectively, these data suggest a ROCK er -mediated NF-κB expression associates with early-stage K14.ROCK er /HK1.ras 1205 papillomatogenesis and may help create the context for malignant conversion via effects on p53 expression 25, 26 and appears necessary for continued malignancy, given the observed susceptibility to elevated levels of p21 following cessation of 4HT treatment.
Tenascin C analysis indicates increasing tissue/ECM rigidity associates with malignant conversion, calling for ROCK2-mediated p-Mypt1 expression to facilitate invasion In normal tissues, ECM expression of tenascin C is low but levels increase during tumour progression and given the interrelationship between ROCK2-associated collagen deposition and resultant integrin mediated in the extracellular matrix, [4] [5] [6] tenascin C levels were analysed to assess stage-specific roles and whether expression reflected increased tissue stiffness. [27] [28] [29] 4HT-treated K14.ROCK er /HK1.ras 1205 papillomas (8 weeks) expressed low tenascin C levels (Figures 7Aa and b) , whereas μm (a, c-e, g);~50 μm (b, f) ).
ras/ROCK2 co-operation in transgenic mouse skin SF Masre et al ras/ROCK2 co-operation in transgenic mouse skin SF Masre et al wdSCC/SCCs exhibited intense staining in carcinoma tissue and elevated ECM staining in surrounding connective tissue (Figure  7Ac-e) . Control HK1.ras 1205 papillomas expressed only weak tenascin C levels in connective tissue ECM, but of note, low-level tenascin C expression was routinely detected in dermal ECM of 4HT-treated K14.ROCK er hyperplasia unlike that of HK1.ras 1205 (Figures 7Af-h) . Following 4HT cessation, the 14-week cohorts of aggressive SCC histotypes displayed intense tenascin C expression in both tumour tissue and connective tissue ECM. In contrast, wdSCC histotypes no longer exhibited tenascin C in tumour tissue ECM but again of note, repeatedly retained expression in connective tissue/ECM (Figures 7Ai-k) . Novel papilloma outgrowths also possessed only sporadic patches of (supra-basal) tenascin C with weak dermal/ECM staining (Figure 7Al ). These data show tenascin C expression depended upon ROCK2 activation and expression appeared significant post p53 loss/conversion, whereas expression in wdSCCs connective tissue ECM post 4HT cessation suggests that once laid down at conversion, tissue rigidity persists in wdSCCs. Thus, to assess the requirement for cell contraction/motility on malignant progression, p-Mypt1 levels were analysed. As anticipated, in 4HT-treated K14.ROCK er /HK1.ras 1205 papillomas, elevated p-Mypt1 expression paralleled ROCK er activation with levels prominent in the invasive fronts/nests of wdSCC/SCCs (above; Figures 7Ba-c) . Following 4HT cessation, SSC areas show persistent p-Mypt1 expression paralleled increasing endogenous ROCK2 activities (above), whereas wdSCC histotypes exhibit reduced expression, consistent with a lack of activated exogenous ROCK er (Figure 7Bd and e) and their inability to invade agressively. In addition, although papilloma outgrowths displayed elevated p-Mypt1, expression was again confined to super-basal layers, alongside supra-basal ROCK2 due to intense basal layer p21 expression. Hence, these data suggest that Mypt1 inactivation is necessary to facilitate changes in actinomyosin/MLC essential to give cells the motility necessary for subsequent invasion of tissues with increased rigidity.
DISCUSSION
These data demonstrate direct co-operation between 4HT-inducible ROCK er and ras Ha activation, such that by 10 weeks, 100% of K14.ROCK er /HK1.ras 1205 papillomas progressed to wdSCC, whereas all untreated cohorts or controls lacked spontaneous malignant conversion. [17] [18] [19] [20] This synergism is consistent with accelerating DMBA/TPA chemical carcinogenesis employing K14. ROCK er mice 5 and identification of ROCK2-associated p-Mypt1ac-tivities in human skin carcinomas 6 and other cancer types. 7, 8 4HT cessation experiments demonstrated that malignant conversion relied upon continued ROCK er activities, unless endogenous ROCK2 activities arose to maintain progression. Thus, deregulated Rho/ROCK2 activation maybe a common synergistic event in ras Ha -initiated carcinogenesis, hence the major efforts geared to developing ROCK inhibitors 3, 8 that may achieve the elusive Achilles heel of successful anti-ras Ha therapies. 20, 30, 31 to investigate potential mechanisms of ROCK2/ fos co-operation.
These data also show that ROCK2 deregulation alone was insufficient to produce tumours requiring ras Ha -mediated initiation 5, 17 and once in sync, in a permissive papilloma environment, the K14.ROCK er -associated features induced malignant conversion. This synergism included a spatial context to tumour progression, as ROCK er /ROCK2 activation in proliferative basal layer keratinocytes was a pre-requisite for malignant conversion and progression, otherwise untreated K14.ROCK er / HK1.ras 1205 and control HK1.ras 1205 papillomas typically displayed a weak endogenous ROCK2 expression profile, with weak p-Mypt1 inactivation confined to post-mitotic, supra-basal layers. Cessation experiments support this idea also, as wdSCCs (12 weeks) relied on ROCK er activation in proliferative basal cells to maintain malignancy, whilst novel papilloma outgrowths lacked basal layer ROCK2/p-Mypt1 expression, whereas later SSCs had acquired endogenous ROCK2 activation/p-Mypt1 inactivation in basal layers. Furthermore, as ROCK2 may contribute to intra-cellular tension/rigidity in normal epidermal differentiation giving tensile strength to spinous layer keratinocytes, 21, 22 the abrupt loss of basal ROCK er expression following 4HT cessation may account for the increased differentiation marker expression observed in wdSCCs and alongside p21 expression 23, 24 induce a differentiation response, given the lack of p53 to induce apoptosis. 32 Previously, such compensatory p53/p21 responses were found to be key features in the mechanism underlying malignant conversion and progression in this skin model. 20, 23 In respect to p53, all 4HT-treated K14.ROCK er /HK1.ras 1205 cohorts lost expression before conversion, beginning in papilloma basal layers. The increased mitotic index following p53 loss and the lack of DNA repair would give rise to additional mutations in highly proliferative cells giving a susceptibility to malignant conversion. 32, 33 Indeed, as outlined below, these K14.ROCK er /HK1. ras 1205 data suggest a mechanism involving p53 loss that links ROCK2-associated NF-κB deregulation to the matrix remodelling that drives progression [34] [35] [36] [37] when coupled with GSK3β/β-catenin/ WNT signalling effects. 5, 23, 38 Overall however, the identification of p21-associated responses may be of most significance, as this appears to limit (early-stage) malignant progression in K14.ROCK er / HK1.ras 1205 carcinogenesis as observed in another version of this model. 20, 23 Despite many studies that show p21 expression is lost alongside that of p53, 39 here as p53 diminished in K14.ROCK er /HK1. ras 1205 papillomas, basal layer p21 expression increased and moreover, persisted in wdSCCs becoming eventually lost on progression to SCC. 20, 23, 40 All wdSCCs exhibited persistent basal layer p21 expression, which exactly paralleled K14.ROCK er /pMypt1 expression, suggesting that increased p21 is a common response to ras/ROCK er /ROCK2 activities. This feature also accounts for malignancy appearing within 10 weeks but progression to SCC required an additional 4-6 weeks, necessitating both p21 loss and continued ROCK er /ROCK2 activities. A p21-ras Ha / ROCK2 antagonism is also suggested by the intense p21 expression observed in papilloma outgrowths following cessation of 4HT. Initially, p21 was elevated in K14.ROCK er /HK1.ras 1205 and control papillomas, but appeared mainly supra-basal, consistent with roles in keratinocyte differentiation. 23, 24 However, the intense p21 expression was unprecedented 20, 23 and appears directly geared to restrict residual ROCK2/p-Mypt1 expression (and NF-κB; ras/ROCK2 co-operation in transgenic mouse skin SF Masre et al below) to their differentiation roles in post-mitotic, supra-basal keratinocytes. 21, 22 Previous studies support antagonism between p21-and ras Ha / ROCK2-mediated malignant progression, 11, 41 as in vitro, Rho kinases functioned to block ras Ha -induced p21 expression; 11 yet activated Rho GTPases did not transform NIH3T3 cells, showing the necessity for ras Ha activation. 11 Later studies demonstrated that ROCK2 affected cyclin D1 activity by regulating p21 levels, 12, 41 and given that p21-mediated inhibition of cyclin D1 was observed in tri-genic ras 1276 /fos/Δ5PTEN flx carcinogenesis, 20 this reinforces stage-specific p21 responses to oncogenic signalling, geared to attempted restoration of cell cycle control, hence the lack of a significant increase in mitotic index in K14.ROCK er /HK1.ras 1205 wdSCCs compared with papillomas. Subsequently, as p21 dissipates during malignant progression, attempts to maintain chromosomal stability following p53 loss are circumvented, 21, 39, 40 and continued 4HT-ROCK er (or endogenous ROCK2 activation) adds ras Ha /ROCK2-mediated cell cycle control failures, for example, increased cyclin D, 12, 20 to highly proliferative cells with increased susceptibility to mutations, and when overlaid with ROCK2/pMypt1-mediated changes to cell motility/tension/ECM, the result is accelerated invasion and metastasis. -mediated NF-κB expression is consistent with activation of NF-κB by Rho-induced, nuclear translocation of p65/RelA, independent of Ras GTPases. 9, 10 Whether this is exerting a protective or oncogenic role in this context is unclear, 25 but elevated NF-κB inflammatory roles would be consistent with wound promotion, currently associated with fos/Jun/AP1 activation, 44 hence whether fos/AP1 promotes via deregulation of NF-κB is under investigation.
In addition to inflammatory/wound promotion roles driving papillomatogenesis, ROCK er -associated NF-κB expression may influence malignant conversion via circumventing the compensatory p53 responses. 26 In papillomas, NF-κB and the axis of ROCK2/ FAK/β-catenin 5, 6 may contribute to the demise of p53, given both NF-κB 26 and FAK-associated β-catenin 38,45 inhibit p53 expression. These papilloma data thus link NF-κB with increased DNA mutations/chromosomal instability 25, 46 following p53 loss and associated p21 inhibition 47 (below), and indirectly link ROCK2-mediated NF-κB to stromal remodelling, 25 thus accounting for the effects previously observed on expression of ECM molecules such as tenascin C. 48, 49 One consequence of p53 loss leading to an altered matrix may involve downregulated microRNAs, 34 such as miR-200 that regulates cell-cell adhesion molecules 35 and effected ROCK signalling in gastric cancer. 36 Of note, p53-mediated miR-200 expression depended upon AKT levels, 37 consistent with p53 loss driving malignant conversion in trigenic HK1.ras/fos/Pten flx carcinogenesis.
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Early NF-κB expression coupled with p53 downregulation in K14.ROCK er /HK1.ras 1205 papillomas 25, 26 would account for increased proliferation, possibly via the NF-κB responsive element regulating cyclin D 42 and, in sync with ROCK2/ras signalling, 12 add to the increasing pool of cycling cells susceptible to DNA damage/ chromosomal re-arrangements. Further following 4HT cessation, as wdSCCs retained NF-κB expression that continued the inhibition of p53, it helps explain the lack of apoptosis 26, 28 and, instead, the system attempts to implement a p21-mediated differentiation response, 24 leading to the confused/disturbed wdSCC architecture. Previously, these combined p53 and p21 responses induced compensatory differentiation levels sufficient to prevent conversion, 23 however, in K14.ROCK er /HK1.ras 1205 papillomas, NF-κB/p53 antagonism 25, 26 coupled to the axis of ROCK2-associated GSK3β inactivation/increased nuclear β-catenin 5, 6, 38, 45 possibly circumvented the p53 arm. 23 Nonetheless, although unable to prevent conversion, persistent p21 remained to inhibited early-stage progression, 20, 23, 40 until lost, thus releasing ras Ha /ROCK2/NF-κB synergism to drive progression further.
The cessation experiments clearly demonstrated the ability of p21 to inhibit ROCK2-mediated progression where intense p21 expression confined both ROCK2 and NF-κB to post-mitotic, suprabasal keratinocytes. This latter result not only shows the requirement for ROCK er -mediated NF-κB expression to facilitate progression, but also demonstrated that p21 responses eliminated NF-κB expression independent of ROCK2 signalling. 43, 47 Furthermore, downregulation of NF-κB paralleled increasing basal layer p53 expression 26 that restored the p21/p53-mediated resistance to malignant conversion. 20, 23 Indeed, this direct p21-mediated antagonism to NF-κB signalling was recently demonstrated in liver carcinogenesis where p21 knockout was shown to be pivotal to progression following loss of NEMO, a major NF-κB pathway regulator. 47 Of relevance to K14.ROCK er /HK1.ras 1205 carcinogenesis, p21 overexpression protected NEMO Dhepa animals against DNA damage, 40, 46 whereas p21 knockout accelerated hepatocarcinogenesis in bi-genic NEMO Dhepa /p21 null mice, 47 thus implicating NF-κB in chromosomal damage. 33, 40, 44, 46 Most major consequences of ROCK2 activation alter the tumour microenvironment and establish a context permissive for stagespecific progression.
1,2,13 Previous K14.ROCK er studies demonstrated ROCK-associated collagen deposition resulted in a stiffened ECM and increased tissue rigidity. 5 Similarly human cutaneous SCCs demonstrated ROCK2/p-Mypt1 staining correlated with MLC2 phosphorylation and actomyosin contractility, 6 suggesting a mechano-transduction pathway facilitated progression by providing the mobility/flexibility necessary to invade tissues with increased rigidity, [6] [7] [8] ideas supported by analysis of tenascin C 28 − 30 and p-Mypt1 inactivation. Tenascin C is a large ECM/molecule associated with alterations in rigidity that drive progression [27] [28] [29] and was previously linked with activated Rho/Rock and MAP kinase signalling. 28, 29 Tenascin C expression reflects tumour aggression and metastatic potential, 27, [48] [49] [50] and also associated with deregulated NF-κB signalling 48 and NF-κB roles in inflammation. 49 Early 4HT-treated K14.ROCK er hyperplasia and K14.ROCK er /HK1.ras 1205 papillomas displayed weak tenascin C levels, despite ROCK er -associated NF-κB expression. With time and/or p53 loss, increased tenascin C expression appeared in the ECM of both wdSCC and surrounding connective tissue, with intense staining appearing as wdSCCs progressed to SCC. [27] [28] [29] [48] [49] [50] The necessity of continued ROCK er activities for tenascin C expression was shown by cessation experiments and again as endogenous ROCK2/p-Mypt1 appeared, intense tenascin C returned in both SCC tumour and connective tissue ECM to facilitate progression. 28, 29 However, following cessation tenascin C repeatedly persisted in wdSCC connective tissue matrix, but not that of tumour tissue, suggesting that once laid down to facilitate conversion, increased tissue rigidity remained. Hence, following cessation ROCK er -dependent wdSCC cells appeared unable to invade, giving rise to the disturbed architecture.
This lack of invasion ability maybe due to the loss of ROCK er mediated p-Mypt1 expression, 5, 6 given that on continued 4HT treatment or rise of endogenous ROCK2, maintenance/return of p-Mypt1 restores p-Mypt1-mediated MLC2 phosphorylation giving increased actomyosin contractility 6 and flexibility/motility for local invasion. Indeed, a feedback mechanism maybe established, ras/ROCK2 co-operation in transgenic mouse skin SF Masre et al
